Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Sponsor: Fudan University
Summary
Establishment and validation of the deep learning signature of bevacizumab efficacy in initially unresectable CRLM patients
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
OBSERVATIONAL
Enrollment
302
Start Date
2023-09-01
Completion Date
2028-07-01
Last Updated
2023-07-13
Healthy Volunteers
No
Conditions
Interventions
Bevacizumab
AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0
Locations (1)
Zhongshan hospital
Shanghai, Shanghai Municipality, China